retatrutide type 2 diabetes trial 2024 💉 may be redefining obesity treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Lilly's triple agonist achieves 16.8%

The researchers further compared all-cause mortality, sepsis- and infection-related mortality, and mortality related to major adverse cardiovascular and cerebrovascular events between patients treated with GLP-1 receptor agonists and patients treated with DPP-4 inhibitors

These highly specific structural modifications are what make this compound a premier subject of study in the fields of cellular hyperplasia and musculoskeletal research

Without the right strategy, they can cost you muscle, energy, and long-term health

Bacteriostatic water contains a preservative, making it safe for the typical 28-day multi-use lifespan of a reconstituted peptide

Novo Nordisk filed a supplemental drug application for Ozempic 25-mg oral tablets for T2DM in adults